Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $1.16M rose 41.0% year over year, ahead of the +10.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 28.8% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.

Context

  • Depreciation & amortization amounted to 225.3% of revenue in FY2025, up 180.1 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +41.0% holds above the trailing-twelve-month pace of +10.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.16M+28.8% QoQ
Last fiscal yearDec 2025
$3.38M+6.4% YoY
LTMSep 2026
$3.73M+10.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.0%——
1 year+6.4%——
3-year CAGR+5.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
3.38M USD
Year-over-year change
+6.4%
4-year CAGR
+2.5%

Depreciation & Amortization vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 depreciation & amortization of $3.73M is the 6th highest of the 10 companies compared; the peer median is $7.09M.
  • Its year-over-year change of +10.4% is the highest of 8, against a peer median of -10.7%.
  • Depreciation & amortization amounts to 3333.9% of revenue for CLDX, versus a peer median of 6.0%.
CLDX Competitors Peer median
Depreciation & Amortization for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$14.4M -22.3%+20.4%2.1%
XNCRXencor, Inc.LTM Jun 2026$10.17M -10.7%+6.1%9.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M +0.0%+18.6%8.5%
AGENAgenus Inc.LTM Mar 2026$7.38M -44.0%+12.9%6.0%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M -5.1%-15.4%4.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M +10.4%+5.3%3333.9%
IMNMImmunome, Inc.LTM Sep 2026$2.69M -3.0%+67.3%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$1.12M -32.0%-8.2%—
ADAGAdagene Inc.LTM Jun 2024$931.31K —-25.6%114.2%
CGENCompugen Ltd.LTM Mar 2026$0 —-0.5%0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $7.09M-10.7%+6.1%6.0%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.